Archive for the ‘Lyme Vaccine’ Category

Study on An Anti-tick Vaccine

https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-019-3468-x

Counterattacking the tick bite: towards a rational design of anti-tick vaccines targeting pathogen transmission

  • Ryan O. M. RegoEmail authorView ORCID ID profileJos J. A. TrentelmanJuan AnguitaArd M. NijhofHein SprongBoris KlempaOndrej HajdusekJulen Tomás-CortázarTal AzagiMartin StrnadSarah KnorrRadek SimaMarie JaloveckaSabína Fumačová HavlíkováMartina LičkováMonika SlávikováPetr KopacekLibor Grubhoffer and Joppe W. Hovius
    Parasites & Vectors201912:229

    https://doi.org/10.1186/s13071-019-3468-x

    Published: 14 May 2019

Abstract

Hematophagous arthropods are responsible for the transmission of a variety of pathogens that cause disease in humans and animals. Ticks of the Ixodes ricinus complex are vectors for some of the most frequently occurring human tick-borne diseases, particularly Lyme borreliosis and tick-borne encephalitis virus (TBEV). The search for vaccines against these diseases is ongoing. Efforts during the last few decades have primarily focused on understanding the biology of the transmitted viruses, bacteria and protozoans, with the goal of identifying targets for intervention. Successful vaccines have been developed against TBEV and Lyme borreliosis, although the latter is no longer available for humans. More recently, the focus of intervention has shifted back to where it was initially being studied which is the vector. State of the art technologies are being used for the identification of potential vaccine candidates for anti-tick vaccines that could be used either in humans or animals. The study of the interrelationship between ticks and the pathogens they transmit, including mechanisms of acquisition, persistence and transmission have come to the fore, as this knowledge may lead to the identification of critical elements of the pathogens’ life-cycle that could be targeted by vaccines. Here, we review the status of our current knowledge on the triangular relationships between ticks, the pathogens they carry and the mammalian hosts, as well as methods that are being used to identify anti-tick vaccine candidates that can prevent the transmission of tick-borne pathogens.

___________________

**Comment**

In the paragraph before the conclusion (in the full-length document) the following is stated:

Given the current health concerns related to LB, a novel vaccine would most likely be highly welcomed by society. On the other hand, the previously commercially available vaccine against LB was taken off the market for various and questionable reasons [232]. Therefore, efforts are needed to address societal prejudices associated with vaccination, including health benefits, risks, and necessity, especially from a public health perspective.

Well if that isn’t the understatement of the year, I don’t know what is.  The LB (Lyme borreliosis) vaccine was yanked off the market because it CAUSED Lyme symptoms in many people, as well as dogs:  https://madisonarealymesupportgroup.com/2018/07/22/why-we-care-so-strongly-about-a-potential-lyme-vaccine/

https://madisonarealymesupportgroup.com/2018/07/01/lyme-vaccine-fail-safety-ignored/  Excerpt:  

In reality, the vaccine was pulled off the market to avoid disclosure of Phase IV data that probably would have shown limited efficacy and significant safety concerns related to LYMErix (11-13). That data has never been publicly released.

Regarding dogs:  https://www.vetinfo.com/canine-lyme-disease-vaccine-side-effects.html  Excerpt:

Cornell University found long-term side effects that paint a different picture of the safety of the canine Lyme disease vaccination.

In some cases, dogs develop Lyme disease anyway. It’s believed that the antibodies in the vaccine can develop into Lyme disease. Research finds dogs develop all the symptoms of Lyme disease up to six weeks after receiving the shot. While tests for the Lyme disease bacteria show up as negative, there are many dogs developing all the symptoms. Left untreated more concerning issues develop.

A number of dogs develop rheumatoid arthritis months or years later. However, the development of acute kidney failure is more alarming. Remember that 90 percent of dogs never become sick and that pulling off ticks before 48 hours eliminates any risk. Many vets feel the benefit of the vaccination is often outweighed by the potential risks.

Seems veterinarians are often wiser than general practitioners.

For a history of the entire Lyme vaccine saga:  https://madisonarealymesupportgroup.com/2018/06/07/the-lyme-vaccine-russian-roulette/  Excerpt:  

It is believed that a rush to create a Lyme disease vaccine led to the mishandling of the disease. Current antibody tests for Lyme disease were manipulated in 1994 at the Dearborn Conference so as to facilitate vaccine development. The two most important indicators of infection were stripped out of serology tests so that the vaccinated would test seronegative. The vast majority of truly infected patients cannot obtain a timely diagnosis leading to a missed opportunity for successful short term treatment.

The vaccine known as LYMErix was supposed to expose the immune system to the outer surface protein A (OspA) of the spirochete responsible for causing Lyme disease but for some patients, it caused the same crippling effects of the disease itself as reported in the class action lawsuit:

https://www.dropbox.com/s/sodqs3pdeeesktf/Sheller%20Lymerix.pdf?dl=0

EXCERPT FROM THE LAWSUIT:

“The people who have contacted us were, prior to vaccination with LYMErix, healthy, active and energetic. Indeed, the very reason they sought the LYMErix vaccine was their desire to preserve their healthy, active lifestyle. However, what they experienced was a dramatic degradation of their health and quality of life. As will be described below, these previously healthy individuals are now afflicted with painful, at times debilitating arthritic symptoms, including joint pain and swelling, as well as extremely severe Lyme-disease-like symptoms which have persisted to this day.”

I counted at least 20 people who authored this study.  Where are the researchers who are studying better testing, effective treatments, transmission studies on all the ways Lyme/MSIDS can be transmitted, post mortem studies to end the Lyme wars, and answers to how patients can pay for this plague?

Researchers for those issues are no where to be found.  If there are any, they are in their own basements using their own microscopes with limited funding.

 

 

Valneva’s Lyme Disease Vaccine on FDA Fast Track Designation

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/24581258?

Valneva’s Lyme disease vaccine on FDA Fast Track Designation

MAY 19, 2019 — 

The letter below was sent to The New Hampshire Medical Society which is the committee given responsibly for further study of New Hampshire House Bill 490.

House Bill 490
https://legiscan.com/NH/text/HB490/id/1962817

Please forward this email to as many contacts that you may have in order to inform the public of the truth behind the mishandling of Lyme disease here in the United States. Lyme patients worldwide have been affected as foreign public health agencies are blindly following what has been deceitfully established here in the US.

Lyme Bumper Stickers (Public Service Announcement)
https://www.ebay.com/itm/123659578861

WAKE UP AMERICA!

——— Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: james.potter@nhms.org, michael.padmore@nhms.org
Cc: Howard.Moffett@leg.state.nh.us, amknh78@gmail.com, Tom.Sherman@leg.state.nh.us, Martha.FullerClark@leg.state.nh.us, Jeb.Bradley@leg.state.nh.us, James.Gray@leg.state.nh.us, Shannon.Chandley@leg.state.nh.us, Doug.Marino@leg.state.nh.us, kathie@kathiefife.com, Polly.Campion@leg.state.nh.us, jc.salloway@unh.edu, wmarshmd@gmail.com, nhbidc@dhhs.nh.gov, saunderson.george@gmail.com, electdavidkarrick@gmail.com, cmcmahon55@gmail.com, jeffrey.meyers@dhhs.nh.gov, cutler_library@comcast.net, brett.giroir@hhs.gov, tickbornedisease@hhs.gov, abigail.mathewson@dhhs.nh.gov
Date: May 18, 2019 at 8:41 AM
Subject: Valneva’s Lyme disease vaccine on FDA Fast Track Designation

To: The New Hampshire Medical Society Advisory Council on Tick and Other Insect Borne Diseases,

Please take a moment to read the following Facebook message I received yesterday regarding a personal experience after receiving the LYMErix vaccine previously FDA approved in 1998.

Contrary to public belief, LYMErix was not pulled from the market in 2002 solely due to low demand. More on that in a moment…….

Beth Leahy
https://www.facebook.com/beth.leahy.77

Hi Carl i have a question. Ty for all your hard work btw. i had the 3 lymerix vaccines in 2000-2001. i am 43 years old and was forced to retire 3 years ago. i have neuro chronic lyme. I have reached out to several forums and organizations asking if anyone would be willing to do any testing on me for free. the benefit to this is i have a twin sister who did not receive the vaccines and has never been bitten. she has agreed to undergo comparative testing with me whether its gene testing or any other testing. we are willing to do anything. Thankfully she is willing to do whatever it is to help me and others. Maybe bc of our unique situation we could help in doing something positive. I have received no response from anyone. i am disappointed because i think its a unique opportunity at least no harm in trying. Can u please ask some of your resources if they are interested? I live near Albany NY but we will travel anywhere. Thank you. my phone # is 518-XXX-XXXX and my name is Beth Leahy. Thank you in advance!! I hope with all your contacts maybe you will have better luck in finding a researcher or dr. who will be interested.

____________________________________

In reference to Beth Leahy’s experience above, please see the following excerpt from the attached REPORT ON LYMErix prepared for the 2001 Advisary Committee Meeting:

Sheller Lymerix
https://www.dropbox.com/s/sodqs3pdeeesktf/Sheller%20Lymerix.pdf?dl=0

“The people who have contacted us were, prior to vaccination with LYMErix, healthy, active and energetic. Indeed, the very reason they sought the LYMErix vaccine was their desire to preserve their healthy, active lifestyle. However, what they experienced was a dramatic degradation of their health and quality of life. As will be described below, these previously healthy individuals are now afflicted with painful, at times debilitating arthritic symptoms, including joint pain and swelling, as well as extremely severe Lyme-disease-like symptoms which have persisted to this day.”

Below is the link to the Final Judgement and Approval of the class action against SmithKline Beecham as a settlement was awarded to these individuals.

JUDGEMENT, FINAL ORDER AND DECREE GRANTING FINAL APPROVAL OF THE CLASS ACTION SETTLEMENT:

https://www.dropbox.com/s/v3gyw4fv8nst9bz/2003_Vaccine_Judgement_Final_Sttle_Apprvl..pdf?dl=0

In addition please see the following study reporting adverse neurological complications:

Int J Risk Saf Med. 2011;23(2):89-96. doi: 10.3233/JRS-2011-0527.

Neurological complications of vaccination with outer surface protein A (OspA).

Marks DH1. http://www.ncbi.nlm.nih.gov/pubmed/21673416

Abstract

A wide range of neurological complications have been reported via the medical literature and the VAERS system after vaccination with recombinant outer surface protein A (OspA) of Borrelia. To explore this issue, 24 patients reporting neurological adverse events (AE) after vaccination with Lymerix, out of a group of 94 patients reporting adverse events after Lymerix vaccination, were examined for causation. Five reports of cerebral ischemia, two transient Ischemic attacks, five demyelinating events, two optic neuritis, two reports of transverse myelitis, and one non-specific demyelinating condition are evaluated in this paper. Caution is raised on not actively looking for neurologic AE, and for not considering causation when the incidence rate is too low to raise a calculable difference to natural occurence.

_________________________________

To: The New Hampshire Medical Society Advisory Council on Tick and Other Insect Borne Diseases,

To my knowledge there was no follow-up research to determine why this class of patient suffered the reaction they experienced. Is there a genetic predisposition that could give a similar reaction to the next OspA vaccine?

Valneva’s Lyme disease vaccine now on FDA Fast Track Designation is yet another OspA vaccine.

TOUCHED BY LYME: Why we care so strongly about a potential vaccine
https://www.lymedisease.org/touchedbylyme-why-we-care-lyme-vaccine/

_________________________________

It is believed that Lyme disease was pigeonholed into its current status by the two principal investigators of the previous Lyme disease vaccines as these investigators conceptualized a disease that would enable vaccine development.

A preventive vaccine for Lyme disease would not satisfy the FDA if a chronic persistent infection and seronegative disease exist. The lead author of the one-size-fits-all IDSA Lyme treatment guideline (which matches the conceptualized disease) was the principal investigator of Connaught’s Lyme vaccine, Dr. Gary Wormser. This is a flagrant conflict of interest. Have we been dealing with an antibiotic resistant/tolerant superbug purposely concealed to promote vaccine development?

When the LYMErix vaccine was pulled from the market the deception had to continue and this is why all the science identifying persistent infection must be ignored.

There are published studies early on describing the destructive nature of borrelia (1988 Paul Duray paper coauthored by Allen Steere, See attached PDF) so Steere and Wormser (Principal investigators of the previous Lyme vaccines) know everything the disabled Lyme community is experiencing. The rush to create a vaccine should have been the tip-off as it was going to be the “cure-all” for an incurable/disabling disease.

Paul Duray paper:

https://www.dropbox.com/s/gjl0cym2mr2phij/1988-clinical-pathologic-correlations-of-lyme-disease-by-stage-Duray.pdf?dl=0

Leaving the CDC in control of Lyme disease under the watch of Health and Human Services will allow this public health crisis to continue.

Anyone who does not see this is turning a blind eye to an immoral act.

Respectfully submitted,

Carl Tuttle

Lyme Endemic Hudson, NH

“Justice will not be served until those who are unaffected are as outraged as those who are.” ― Benjamin Franklin

____________________

For more:  https://madisonarealymesupportgroup.com/2018/01/28/the-secret-x-files-the-untold-history-of-the-lymerix-vaccine/

https://madisonarealymesupportgroup.com/2018/07/22/why-we-care-so-strongly-about-a-potential-lyme-vaccine/

https://madisonarealymesupportgroup.com/2018/07/01/lyme-vaccine-fail-safety-ignored/

https://madisonarealymesupportgroup.com/2018/06/07/the-lyme-vaccine-russian-roulette/%20https://

https://madisonarealymesupportgroup.com/2017/07/01/pbs-lyme-vaccine/

When Lyme Disease Doesn’t Go Away

https://news.columbia.edu/news/when-lyme-disease-doesnt-go-away

When Lyme Disease Doesn’t Go Away

It’s tick season. Here’s what Brian Fallon, the director of Columbia’s Lyme & Tick-borne Diseases Research Center, has to say about combating chronic Lyme disease.
By

Carla Cantor
April 29, 2019

Brian A. Fallon, (VP&S ’85, MPH ’85) spent his early career working with patients whose medical symptoms were a mystery. The Columbia University Irving Medical Center psychiatrist became one of the foremost researchers of hypochondria and somatic disorders, or psychological illness that manifests as physical symptoms.

He might have stayed with that specialty had he not begun in the early 1990s to see a surge in referrals of patients with chronic, unexplained symptoms who had all been healthy—until they got Lyme disease. These patients suffered from chronic pain, fatigue and cognitive problems that had a debilitating effect on their lives. They all had been treated with antibiotics with partial response but then relapsed.

Since such persistent infection was considered impossible, they were told they were hypochondriacs.

“At the time, the medical community was saying that initial antibiotic therapy led to a cure,” Fallon said. “I found this hard to believe given the suffering among these patients. We needed to look further.”

Since 2007 Fallon has headed Columbia’s Lyme & Tick-borne Diseases Research Center, a joint effort by the Global Lyme Alliance, the Lyme Disease Association and the Columbia University Medical Center Board of Trustees. It is the first such academic research center in the country, and its mission is to tackle the core clinical questions of the disease and identify better diagnostics, biomarkers and treatments.

Fallon discusses why this is a pivotal time in the world of Lyme disease.

Book cover of Conquering Lyme Disease

Q. Lyme disease was first reported in the United States in 1977 in the town of Old Lyme, Connecticut.  How far have we come?

A. We still have many unanswered questions, but there has been tremendous progress. We now know the cause of the disease, a bacterium called Borrelia burgdorferi, and its multi-system manifestations. We know many of the biologic tricks the organism uses to evade the human immune response and we know its genetic makeup, as it has been fully sequenced. We know that while most Borrelia are easily eradicated with a standard course of antibiotics, some persist despite treatment. We briefly had a vaccine on the market, which is no longer available, but a new vaccine is now in clinical trials. Despite advances in some areas, there remain serious problems, most prominently that the epidemic of Lyme disease continues to expand both geographically and in the number of new cases—an estimated 400,000 in the United States each year.

Q. What are the symptoms of chronic Lyme disease and how is it diagnosed? What percentage of Lyme sufferers go on to have chronic problems?

A. Most patients do well if the infection is recognized and treated early. In about 10 to 20 percent of cases, patients develop a more severe disease whose symptoms can include debilitating pain, fatigue, headaches, mental fog causing difficulty with memory or finding words, irritability and  sleep disorders. Unfortunately, because our blood tests are antibody-based and can remain positive for years even when infection is no longer present, it is hard to determine whether a patient’s recurrent symptoms are due to persistent infection, a new infection or a post-infectious disorder.

Q. Why does post-treatment Lyme disease affect some people and not others?

A. This is an important question for which we have only preliminary answers. Infection by a more invasive strain of the Borrelia microbe, rather than one that only causes skin manifestations, increases the risk of more severe disease. Certain genetic markers increase the risk of chronic Lyme arthritis. Patients with a history of multiple physical illnesses and other life stressors may have less resilience to infection. And because the tick may transmit other microbes, some patients may have two or more infections.

Q. What are the current treatments for persistent Lyme disease?

A. There are multiple approaches to the treatment of lingering symptoms, but there haven’t been any new, large clinical trials in the U.S. on chronic Lyme-related symptoms in over 10 years. Studies in Europe of early Lyme disease indicate that some of these patients improve without further treatment over the course of one year after initial antibiotic therapy. Patients with chronic symptoms need a personalized approach based on the cause of their symptoms.

Q. Is there hope of finding a cure?

A. Absolutely. With precision medicine approaches, biomarkers are now emerging that appear able to predict who might respond to standard antibiotic therapy and those who might not. This provides an opening for testing new treatment approaches for the latter group, leading to improved long-term outcome.


Dr. Fallon is co-author of Conquering Lyme Disease: Science Bridges the Great Dividewith Dr. Jennifer Sotksy ( VP&S’16,) a fourth-year psychiatry resident at Columbia University Irving Medical Center. (Columbia University Press, 2017 hardcover,  2019 paperback)

For media inquiries or more information, contact Carla Cantor at 212-854-5276 or carla.cantor@columbia.edu.

__________________

**Comment**

  • Again, the erroneous percentages of 10-20% of patients going on to develop persistent symptoms is inaccurate.  There’s a whole lot more of us out here in Lyme-land than that.  Please read:  https://madisonarealymesupportgroup.com/2019/02/25/medical-stalemate-what-causes-continuing-symptoms-after-lyme-treatment/  In a nutshell, microbiologist Holly Ahern points out that the 10-20% the CDC calls PTLDS only includes those patients diagnosed and treated early.  It does not and should not include a large subset of patients (30-40%) diagnosed and treated late.  When you add the two groups together, you get 60% of patients going on to struggle with persisting symptoms.  This is an important detail as it shows the vast numbers struggling as well as the need for high priority research studying this issue.  

 

  • He discusses strains of borrelia.  I learned something the other day – that borrelia (Lyme) is unique in that bacteria are typically only allowed 1 species name, but due to honoring Willy Burgdorfer, all borrelia are “Lyme.” This little fly in the ointment is a huge reason many are not getting diagnosed.  Current 2-tiered testing only tests for 1 strain. I was told by a researcher to think of the Borrelia burgdorferi sensu lato complex as an umbrella, and the 23 genospecies are dangling from it (soon to be 24, BTW!) This may be why Southerners struggle with getting a diagnosis. STARI may be one of these borrelia that doesn’t fit into the box researchers have created for this night-mare.

 

 

  • He also found IV’s give much higher blood levels of drugs than orals, and that the following variables necessitated IV treatment:
    1. Spinal tap shows high inflammation (high protein)
    2. High Sed rate and synovitis (inflammation of synovial membrane)
    3. People sick for more than 1 year
    4. Age over 60
    5. Acute carditis
    6. Immune deficiency
    7. Those who used immunosuppressants
    8. Failed oral treatment

 

  • If you study this for 1 second you begin to appreciate the complexity of treating this which mainstream doctors still haven’t even accepted.

 

  • The fact that there haven’t been any new, large clinical trials in the U.S. on chronic Lyme-related symptoms in over 10 years is unacceptable when you consider that this is two times more prevalent than breast cancer.  HELLO?  Where’s the green ribbons and huge institutions raising funds for Lyme research?  Oh, yeah, I remember, our researchers are using their own microscopes in their basements!  https://lymelifescapeswithcaroline.com/2014/03/25/dr-alan-b-macdonald/  MacDonald is shown in the documentary, “Under Our Skin.”  

 

  • BTW: when MacDonald presented his culture findings (direct testing) at a meeting of the NY State medical society where there were many detractors from Yale & Stoneybrook who didn’t want their patented serological tests to be usurped. They accused him of falsifying his results.  Dr. McDonald then went on to prove conclusively it was Lyme by morphology, silver staining, monoclonal antibodies staining, DNA PCR and finally electron microscopy.  Frustrated, he quit the field and moved to Texas leaving all his old files in Burrascano’s basement until twenty years went by and he became interested again due to Alzheimer’s research & picked up his old files. https://madisonarealymesupportgroup.com/2019/02/22/why-mainstream-lyme-msids-research-remains-in-the-dark-ages/

 

 

 

 

 

Lyme & Reason: Interviews with Advocates & Researchers

 Approx. 20 Min

Lyme & Reason: Battles & Breakthroughs Against Lyme Disease

Published on Sep 5, 2018

It’s a battle that has been raging for decades – the battle against Lyme Disease. Over the years, progress has been made against this dreaded tick-borne illness. But with breakthroughs come even more barriers. Watch this early peek at a new Fox 5 News special on the fight that could be signaling a new chapter in the ongoing bout against Lyme.
  • Interview with President and CEO of Valneva, Thomas Lingelbach on the Lyme Vaccine
  • Interview with Dr. Sung Lee on Lyme testing and his lawsuit against the CDC
  • Interview with Olivia Goodreau of LivLyme – an organization that raises money for research

Lemons & Lyme Part 2

https://www.change.org/p/1120418/u/23307673?

Lemons and Lyme by Stanley Plotkin (Part 2)

Carl Tuttle
Hudson, NH

SEP 22, 2018 —
Please see the letter below addressed to Theoklis Zaoutis, MD, EDITOR-IN-CHIEF of the Journal of the Pediatric Infectious Diseases Society regarding Plotkin’s commentary on the Lyme vaccine. A copy of this letter was forwarded to the Tick Borne Disease Working Group.

ldmIkyMICnZMVyY-800x450-noPad

Wikipedia Plotkin page: https://en.wikipedia.org/wiki/Stanley_Plotkin

——— Original Message ———-
From: Carl Tuttle <runagain@comcast.net>
To: zaoutis@email.chop.edu
Cc: stanley.plotkin@vaxconsult.com, chris.smith@mail.house.gov, collin.peterson@mail.house.gov, ddutko@hanszenlaporte.com, evpdean@upenn.edu, JPIDS.EditorialOffice@oup.com, paul.spearman@cchmc.org
Date: September 22, 2018 at 8:32 AM
Subject: Fwd: Lemons and Lyme by Stanley A. Plotkin
Journal of the Pediatric Infectious Diseases Society

13 September 2018 P L O T K I N C O L U M N
Lemons and Lyme
https://academic.oup.com/jpids/advance-article-abstract/doi/10.1093/jpids/piy083/5094865?redirectedFrom=fulltext
Stanley A. Plotkin
Emeritus Professor of Pediatrics, University of Pennsylvania, Doylestown

Excerpt:

“It is odd that there is a lobby against the development and deployment of a vaccine against the disease by people who think they are suffering from Lyme infection in a chronic form, the existence of which remains doubtful. They believe that the first vaccine against Lyme disease caused chronic arthritis.”

Sept 22, 2018
The Journal of the Pediatric Infectious Diseases Society
Oxford University Press
2001 Evans Road
Cary, NC 27513
ATTN: Theoklis Zaoutis, MD, MSCE, EDITOR-IN-CHIEF

Dear Dr. Zaoutis,
In reference to Dr. Plotkin’s statement above, please see the following excerpt from the attached REPORT ON LYMErix prepared for the 2001Advisary Committee Meeting:
https://www.dropbox.com/s/sodqs3pdeeesktf/Sheller%20Lymerix.pdf?dl=0

“The people who have contacted us were, prior to vaccination with LYMErix, healthy, active and energetic. Indeed, the very reason they sought the LYMErix vaccine was their desire to preserve their healthy, active lifestyle. However, what they experienced was a dramatic degradation of their health and quality of life. As will be described below, these previously healthy individuals are now afflicted with painful, at times debilitating arthritic symptoms, including joint pain and swelling, as well as extremely severe Lyme-disease-like symptoms which have persisted to this day.”

Below is the link to the Final Judgement and Approval of the class action against SmithKline Beecham as a settlement was awarded to these individuals.

JUDGEMENT, FINAL ORDER AND DECREE GRANTING FINAL APPROVAL OF THE CLASS ACTION SETTLEMENT:
https://www.lymediseaseassociation.org/images/NewDirectory/Government/Vaccines/2003_Vaccine_Judgement_Final_Sttle_Apprvl..pdf

In addition please see the following study reporting adverse neurological complications:  Int J Risk Saf Med. 2011;23(2):89-96. doi: 10.3233/JRS-2011-0527.
Neurological complications of vaccination with outer surface protein A (OspA).
Marks DH1. http://www.ncbi.nlm.nih.gov/pubmed/21673416

Abstract
A wide range of neurological complications have been reported via the medical literature and the VAERS system after vaccination with recombinant outer surface protein A (OspA) of Borrelia. To explore this issue, 24 patients reporting neurological adverse events (AE) after vaccination with Lymerix, out of a group of 94 patients reporting adverse events after Lymerix vaccination, were examined for causation. Five reports of cerebral ischemia, two transient Ischemic attacks, five demyelinating events, two optic neuritis, two reports of transverse myelitis, and one non-specific demyelinating condition are evaluated in this paper. Caution is raised on not actively looking for neurologic AE, and for not considering causation when the incidence rate is too low to raise a calculable difference to natural occurence.
________________________________

Dr. Zaoutis, to my knowledge there was no follow-up research to determine why this class of patient suffered the reaction they experienced. Is there a genetic predisposition that could give a similar reaction to the next OspA vaccine?
It would appear that Plotkin has used your journal as a pulpit to broadcast his propaganda. The peer-review process in this case was unsuccessful in determining suitability for publication.

Respectfully Submitted,
Carl Tuttle
Lyme Endemic Hudson, NH
Cc: Julie Weber-Roark MANAGING EDITOR
Attorney Daniel Dutko of Hanszen Laporte
The Honorable Chris Smith and Collin Peterson
Paul Spearman, MD, FPIDS: President, Pediatric Infectious Diseases Society

________________

For more:  https://madisonarealymesupportgroup.com/2018/09/20/lemons-lyme-by-stanley-plotkin/

https://madisonarealymesupportgroup.com/2018/07/01/lyme-vaccine-fail-safety-ignored/

https://madisonarealymesupportgroup.com/2018/07/22/why-we-care-so-strongly-about-a-potential-lyme-vaccine/

https://madisonarealymesupportgroup.com/2017/07/01/pbs-lyme-vaccine/

https://madisonarealymesupportgroup.com/2018/01/28/the-secret-x-files-the-untold-history-of-the-lymerix-vaccine/

https://madisonarealymesupportgroup.com/2016/08/04/vaccine-injuries-and-the-lyme-connection/

 

How to Spot the Symptoms of Lyme Disease in Dogs

https://www.thesprucepets.com/lyme-disease-in-dogs-3384701

How to Spot the Symptoms of Lyme Disease in Dogs

Lyme disease is caused by a bacteria called Borrelia burgdorferi and is spread by ticks. Ticks become infected with the bacteria by feeding on infected mice and other small animals. When an infected tick bites other animals, it can transmit the bacteria to these animals. Lyme disease is transmitted by the deer tick (black-legged tick) and a small group of other closely related ticks. The deer tick is small and may bite animals and people without being detected. Lyme disease affects a variety of species, including dogs, cats, and people. Up to 95 percent of dogs infected with B. burgdorferi do not develop symptoms (people are much more likely to become ill with Lyme disease).

There is no evidence that Lyme disease is spread by direct contact with infected animals. However, keep in mind that ticks can hitch a ride home on your pets and move on to the humans in the household. **Please see my comment at end of article**

Risk Factors

Dogs that spend a lot of time outdoors, especially in the woods, bush, or areas of tall grass are most commonly infected with Lyme disease. However, ticks can be carried into yards on other animals, and dogs can become infected anywhere ticks are found.

Infections occur during tick season (usually spring through early fall), but the time between infection and the appearance of Lyme disease symptoms can be up to 2-5 months. **Please see comment**

Lyme disease is seen across the US and in many other parts of the world. In the US. Lyme disease is most common in the northeastern US, along with the Pacific coast, and in the midwest.

Signs of Lyme Disease

When clinical signs do develop, they may be transient or recurrent, and can include:

  • Fever.
  • Decreased appetite.
  • Swollen, painful joints (dogs may be reluctant to move).
  • Lameness — limping which may be mild at first, then worsen, and may also shift from one leg to another.
  • Lethargy.
  • Swollen lymph nodes.

Some dogs with Lyme disease may develop kidney disease.

Signs of kidney disease may include depression, vomiting, loss of appetite, and increased thirst and urination (sometimes a lack of urination will develop). Dogs who develop kidney disease can become very ill and may not respond to treatment.

Neurological disease (behavioral changes, seizures) and heart complications, which are sometimes seen in humans, are rare in dogs.

Diagnosis of Lyme Disease

The diagnosis of Lyme disease must be based on a combination of factors, including history (tick exposure), clinical signs, finding antibodies to B. burgdorferi bacteria, and a quick response to treatment with antibiotics.

A positive antibody test is not enough to make a diagnosis on its own, because not all dogs that are exposed to B. burgdorferi get sick, and antibodies can persist in the blood for a long time after exposure.

Other diagnostic testing, such as blood and urine tests, x-rays, and sampling of joint fluid, may be done to check for signs of kidney disease and to rule out other conditions with similar signs and symptoms.

Treating Lyme Disease

Treatment with antibiotics usually produces rapid improvement in symptoms (antibiotics will be continued for a few weeks). Treatment may not be completely clear the bacteria, but produces a state where no symptoms are present (similar to the condition in dogs that don’t have symptoms from infection).

Kidney disease may develop some time after the initial infection, so is it a good idea to regularly check for excess protein in the urine of dogs that have had Lyme disease. Catching the kidney disease early in its course offers the best prognosis. If kidney disease is present, a longer course of antibiotics along with additional medications to treat the kidney disease is usually necessary.

Preventing Lyme Disease
  • Tick Control is extremely important for the prevention of Lyme disease (and many other diseases that can be transmitted by ticks). Check your dog daily for ticks and remove them as soon as possible, since ticks must feed for at least 12 hours (possibly 24-48 hours) before transmitting the bacteria causing Lyme disease. This is especially important in peak tick season and after your dog spends time in the bush or tall grass (consider avoiding these areas in tick season).  Products that prevent ticks such as monthly parasite preventatives (e.g., Frontline®, Revolution®) or tick collars (e.g., Preventic®) can be used; be sure to follow your veterinarian‘s advice when using these products. Keep grass and brush trimmed in your yard, and in areas where ticks are a serious problem, you can also consider treating your yard for ticks.  **Again, please see my comment at end of article**
  • Vaccines for Lyme Disease: Vaccination against Lyme disease is a controversial topic and is something that should be discussed in depth with your veterinarian. Many specialists do not recommend routine vaccination because so few dogs develop symptoms of Lyme disease, and when Lyme disease does occur in dogs, it is usually readily treated. Additionally, because arthritis and kidney problems associated with Lyme disease are at least partly related to the immune response to the bacteria (rather than the bacteria itself), there is concern that vaccination may contribute to problems. Vaccination is also not 100 percent effective, and it’s only helpful in dogs that have not already been exposed to B. burgdorferi. However, vaccination before exposure can help prevent dogs from getting Lyme disease and also prevent them from becoming a carrier of the bacteria. Where vaccines are used, it is usually recommended to start vaccinating dogs as young puppies (e.g., at around 12 weeks, with a booster 2-4 weeks later). The vaccine does not provide long-lasting immunity, so annual re-vaccination (ideally before tick season) is necessary. The recombinant form of the vaccine is considered to have less potential for side effects than the bacteria form of the vaccine.
Please note: this article has been provided for informational purposes only. If your pet is showing any signs of illness, please consult a veterinarian as quickly as possible.
_________________
**Comment**
While there are many useful take-aways from this article, a number of myths continue to be propagated.  
  1. There is evidence that there is transmission by direct contact with animals.  http://www.lymerick.net/Transmission-Bb-contact.htm  (Here we see evidence of Bb in feces, urine, tick excretes, cow milk, food, in utero, transplacental, sexual, semen, and mucus membranes.)
  2. My vet treated my dog for longer than a couple of weeks.  I think that wise knowing the organism reproduces slowly.  They also have the canine equivalent of probiotics but they are designed for a dog’s micro biome so don’t give him yours.
  3. The fallacy of it taking 24-48 hours to be transmitted, is just that – a fallacy.  Please read more about transmission time here:  https://madisonarealymesupportgroup.com/2017/04/14/transmission-time-for-lymemsids-infection/
  4. Transmission can occur at ANY TIME of the YEAR.  I have buddies pulling live ticks off their dogs in Northern Wisconsin in February.

Also, please note the comments about the vaccine.  They always want to state how great it is in animals but I see many comments that suggest extreme caution – similarly to the human Lyme vaccine.  First, it doesn’t provide lasting immunity, it causes obvious side-effects, it’s not 100% effective, and vaccination can make things worse for dog exposed to Bb.  Since this can be transmitted congenitally, it’s pretty hard to know what dogs already have Bb.  It’s Russian Roulette with dogs just as much as with humans.  Buyer beware.

The NY Times & the Question of a Lyme Vaccine

https://www.lymedisease.org/touchedbylyme-ny-times-vaccine/

TOUCHED BY LYME: The NY Times and the question of a Lyme vaccine

By Dorothy Kupcha Leland, August 14, 2018

The New York Times ran an article today under the headline: Lyme disease is spreading fast. Why isn’t there a vaccine?

Most troubling to me is how the article quotes certain people in a way that totally misrepresents who they are.

Here’s a worrisome case in point:

The article states: Dr. Stanley A. Plotkin, an emeritus professor of pediatrics at the University of Pennsylvania, said that the loss of the vaccine was a “public health fiasco.” He and other researchers said that in the years since, public opposition prevented drug companies from investing in another vaccine that could fail on the market.

It is true that Plotkin is an emeritus professor. It’s also true that he has been a paid consultant to vaccine manufacturers for years. (A simple Google search turns that up.) Shouldn’t that be mentioned in the article? Doesn’t that put his comments in a different light?

Interesting to note that the “public health fiasco” link in the paragraph above goes to a pro-vaccine op-ed that Plotkin wrote for the New York Times in 2013. That article also failed to disclose that its author was a paid consultant for vaccine interests at the time of publication. Seems like a serious oversight to me.

Here’s another illustration:

The article states: Dr. Phillip J. Baker, the executive director of the American Lyme Disease Foundation, a nonprofit group run by volunteers, predicted that opposition from Lyme groups that are suspicious of the medical establishment would hinder any vaccine’s prospects.

It’s true. Baker is executive director of the American Lyme Disease Foundation. But what is that group and who does it represent?

Astroturf

The ALDF is what can be termed an “astroturf organization.” It masquerades as a grassroots group whose name offers no hint of the special interests behind it. (See: The bogus grassroots of the American Lyme Disease Foundation.)

In fact, ALDF is a front organization for the Infectious Diseases Society of America (IDSA). Virtually all of its board members and scientific advisors are members of the IDSA. Several are co-authors of the odious 2006 IDSA Lyme treatment guidelines—which the Lyme community views as being one of the major stumbling blocks for patients seeking appropriate diagnosis and treatment of Lyme disease.

Plain and simple, ALDF does not represent Lyme patients.

Our letter to HHS

In August of 2017, the Department of Health and Human Services (HHS) was poised to choose representatives of Lyme patients for its Tick-Borne Disease Working Group.

The Lyme community was deeply worried that the ALDF might be chosen to “represent” us.

At that time, LymeDisease.org sent a letter to HHS—co-signed by 48 other Lyme patient organizations—stating in part:

The undersigned advocates and representatives of the Lyme and tick-borne diseases community are advising you that the American Lyme Disease Foundation (ALDF) does not represent patients. We respectfully request that you not award that organization any of the spaces reserved for patients on the federal Tick-Borne Working Group established by the 21st Century Cures Act.

The ALDF represents the interests of researchers affiliated with the Infectious Diseases Society of America (IDSA). Yet it portrays itself to the press and others as a patient organization.

In closing, our letter stated:

As real grassroots support groups representing real patients with Lyme disease, we want to make clear that the ALDF does not represent the interests of people with Lyme and other tick-borne diseases. We regard the ALDF’s positions and statements regarding Lyme disease as harmful to patients.

To our relief, no patient/advocate seats on the Working Group were awarded to the ALDF.

Click here to read the whole letter: https://www.lymedisease.org/wp-content/uploads/2018/08/ALDF-letter.pdf

Clarifying where views actually come from

The issue of bringing a Lyme vaccine to market is heating up. There will likely be lots of articles airing lots of differing opinions in the coming months.

I’m not saying that reporters shouldn’t cover varying viewpoints regarding this contentious topic. But it’s essential to clarify where those viewpoints actually come from. Paid consultants to vaccine companies should be labeled as such. Organizations that don’t represent patients should not be allowed to speak for us.

The following blogs cover more aspects of the Lyme vaccine debate:

https://www.lymedisease.org/touchedbylyme-why-we-care-lyme-vaccine/

https://www.lymedisease.org/touchedbylyme-powerful-patients/

https://www.lymedisease.org/lyme-vaccine-failed-safety-concerns/

https://www.lymedisease.org/vaccine-chapter-of-cure-unknown/

TOUCHED BY LYME is written by Dorothy Kupcha Leland, LymeDisease.org’s Vice-president and Director of Communications. She is co-author of When Your Child Has Lyme Disease: A Parent’s Survival Guide. Contact her at dleland@lymedisease.org .

________________

**Comment**

Regarding that last link, a lot has happened since both the 1998 Lyme vaccine and Weintraub’s 2008 book that declares the Lyme vaccine caused “rare” adverse events.
https://madisonarealymesupportgroup.com/2018/04/16/vl15-lyme-vaccine-another-fraud/ THIS VACCINE CAUSED 229 DEATHS, INCLUDING 43 SUICIDES

https://madisonarealymesupportgroup.com/2018/01/28/the-secret-x-files-the-untold-history-of-the-lymerix-vaccine/  (Dr. Lapenta lists all the adverse events and how many suffered with them),  https://madisonarealymesupportgroup.com/2018/04/16/vl15-lyme-vaccine-another-fraud/https://madisonarealymesupportgroup.com/2017/07/01/pbs-lyme-vaccine/

In a vile cesspool of conflicts of interest are university patent holders, drug companies, and the FDA itself as another patent holder. It generated 40 million dollars before it was yanked.

Besides, death and suicide, please see:
http://www.yourlawyer.com/topics/overview/lymerix  One doctor stated that 21 patients developed severe arthritis after receiving the LYMERIX vaccine.

http://www.lymediseaseassociation.org/index.php/about-lyme/controversy/vaccine/261-lymerix-meeting “Given that Dr. Marks lead the clinical trials for Lymerix’s competitor, the OspA vaccine produced and then abandoned by Aventis Pasteur, his conclusions mean a lot. “In my opinion,” he told FDA officials, “there is sufficient evidence that Lymerix is causally related to severe rheumatologic, neurologic, autoimmune, and other adverse events in some individuals. This evidence is such as to warrant a significantly heightened degree of warnings and possible limitations or removal from marketing of Lymerix.”

Dr. Stricker states:
Another Lyme OspA Vaccine Whitewash
The meta-analysis by Zhao and colleagues comes to the conclusion that “the OspA vaccine against Lyme disease is safe and its immunogenicity and efficacy have been verified.” The authors arrive at this sunny conclusion by excluding 99.6% of published articles that demonstrate potential problems with the OspA vaccine. Furthermore, the authors ignore peer-reviewed studies, FDA regulatory meetings and legal proceedings that point to major problems with OspA vaccine safety (1-3). This whitewash bodes ill for future Lyme vaccine candidates because it fosters disregard for vaccine safety among Lyme vaccine manufacturers and mistrust among potential Lyme vaccines.

https://madisonarealymesupportgroup.com/2018/04/28/new-lyme-vaccine-pushed-same-vaccine-corruption-revealed/
Weintraub’s article states that when considering vaccines one has to weigh the risk of the vaccine against the possible adverse reactions – which is true; however, we need to first start with being honest about the number of people with adverse reactions. In doing this, two things are important to keep in mind: 1) All numbers on ALL issues regarding Lyme/MSIDS are notoriously low. 2) ALL numbers on ALL issues regarding vaccines are notoriously low and downplayed.

Since 2008, more has come out about the ability of vaccines to reactivate latent infections: https://madisonarealymesupportgroup.com/2016/04/24/gardasil-and-bartonella/
https://madisonarealymesupportgroup.com/2017/12/02/scottish-doctor-gives-insight-on-lyme-msids/
This is an extremely important point to acknowledge as mainstream medicine STILL hasn’t even accepted the fact Lyme/MSIDS patients are often infected with far more than Lyme (Borrelia) to begin with. The current news that vaccines can activate even latent infections muddies and troubles the waters further and frankly spells doom to Lyme/MSIDS patients.

Personally, every single Lyme/MSIDS patient I know who has undergone vaccination has relapsed. That’s kind of a big deal.

This issue of problems with vaccines has exploded in recent years with new discoveries of contamination: https://madisonarealymesupportgroup.com/2017/10/15/vaccines-and-retroviruses-a-whistleblower-reveals-what-the-government-is-hiding/
https://madisonarealymesupportgroup.com/2018/04/28/italian-lab-shut-down-about-to-testify-about-vaccine-contamination-damage/
This contamination could very well be contributing to disease epidemics, including Lyme/MSIDS: https://madisonarealymesupportgroup.com/2018/03/01/vaccines-could-contribute-to-disease-epidemics-due-to-retrovirus-contamination/

The first-ever study involving a truly unvaccinated population suggests that: fully vaccinated children may be trading the prevention of certain acute illnesses (chicken pox, pertussis) for more chronic illnesses and neurodevelopmental disorders like ADHD and Autism. The scientists also found that children born prematurely, who were vaccinated, were 6.6 times more likely to have a neurodevelopmental disorder. https://madisonarealymesupportgroup.com/2017/05/18/first-peer-reviewed-study-of-vaccinated-vs-unvaccinated-children/